ATE430746T1 - Crf-rezeptor-antagonisten und zugehörige verfahren - Google Patents

Crf-rezeptor-antagonisten und zugehörige verfahren

Info

Publication number
ATE430746T1
ATE430746T1 AT05814807T AT05814807T ATE430746T1 AT E430746 T1 ATE430746 T1 AT E430746T1 AT 05814807 T AT05814807 T AT 05814807T AT 05814807 T AT05814807 T AT 05814807T AT E430746 T1 ATE430746 T1 AT E430746T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
crf receptor
associated methods
crf
pharmaceutically acceptable
Prior art date
Application number
AT05814807T
Other languages
English (en)
Inventor
Marion Lanier
Manisha Moorjani
John TELLEW
John P Williams
Original Assignee
Smithkline Beecham Cork Ltd
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd, Neurocrine Biosciences Inc filed Critical Smithkline Beecham Cork Ltd
Application granted granted Critical
Publication of ATE430746T1 publication Critical patent/ATE430746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05814807T 2004-10-19 2005-10-17 Crf-rezeptor-antagonisten und zugehörige verfahren ATE430746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62001204P 2004-10-19 2004-10-19
PCT/US2005/037295 WO2006044821A1 (en) 2004-10-19 2005-10-17 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE430746T1 true ATE430746T1 (de) 2009-05-15

Family

ID=35696119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814807T ATE430746T1 (de) 2004-10-19 2005-10-17 Crf-rezeptor-antagonisten und zugehörige verfahren

Country Status (7)

Country Link
US (1) US7652035B2 (de)
EP (1) EP1802621B1 (de)
JP (1) JP2008517060A (de)
AT (1) ATE430746T1 (de)
DE (1) DE602005014375D1 (de)
ES (1) ES2326827T3 (de)
WO (1) WO2006044821A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EA037544B1 (ru) * 2017-04-04 2021-04-12 Х. Лундбекк А/С ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
EP3723807B1 (de) * 2017-12-14 2021-10-20 H. Lundbeck A/S Kombinationsbehandlungen mit verabreichung von 1h-pyrazolo[4,3-b]pyridinen
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
WO2019121840A1 (en) * 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
EP3774739B1 (de) * 2018-04-09 2022-05-11 RaQualia Pharma Inc. Kondensierte cyclische harnstoffderivate als crhr2-antagonisten
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
JP3621706B2 (ja) * 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
WO1999045002A1 (en) * 1998-03-04 1999-09-10 Kyowa Hakko Kogyo Co., Ltd. Benzofuran derivatives
US6613777B1 (en) * 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PL354784A1 (en) * 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
DE60225127T2 (de) * 2001-04-30 2009-02-19 Glaxo Group Ltd., Greenford Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
EP1395591B1 (de) * 2001-06-12 2008-06-04 Glaxo Group Limited Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
WO2003048160A1 (en) * 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Ring fused pyrazole derivatives
WO2004062665A1 (en) * 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
JP2007515474A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
EP1812008A4 (de) * 2004-10-20 2008-10-29 Smithkline Beecham Corp Il-8-rezeptorantagonisten

Also Published As

Publication number Publication date
WO2006044821A8 (en) 2006-08-24
JP2008517060A (ja) 2008-05-22
WO2006044821A1 (en) 2006-04-27
DE602005014375D1 (de) 2009-06-18
US20080064719A1 (en) 2008-03-13
EP1802621B1 (de) 2009-05-06
US7652035B2 (en) 2010-01-26
ES2326827T3 (es) 2009-10-20
EP1802621A1 (de) 2007-07-04

Similar Documents

Publication Publication Date Title
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
TW200626599A (en) CRF receptor antagonists and methods relating thereto
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
EA201070238A1 (ru) Соединения пиримидина
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MX2010007392A (es) Antagonistas de trpa1.
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MX2010007391A (es) Antagonistas de trpa1.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
DE69903333D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
IL206359A0 (en) Sulfonamides as orexin antagonists
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties